Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
216.37
+4.48 (+2.11%)
Streaming Delayed Price
Updated: 2:14 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
39
40
Next >
Could Eli Lilly Leapfrog Biogen in This Market?
November 17, 2021
Biogen is benefiting from a first-mover advantage, but the race is far from over.
Via
The Motley Fool
Europe OKs Biogen's Vumerity For Multiple Sclerosis
November 16, 2021
The European Commission has approved Biogen Inc's (NASDAQ: BIIB) Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS...
Via
Benzinga
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
November 16, 2021
Warren Buffet's Berkshire Hathaway added more than 13 million shares.
Via
Investor's Business Daily
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment
November 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis...
Via
Benzinga
Expert Ratings For Biogen
October 26, 2021
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) with...
Via
Benzinga
Analyst Ratings For Biogen
October 21, 2021
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) with...
Via
Benzinga
Google, Tesla Rival XPeng Lead 5 Stocks Near Buy Zones
November 13, 2021
A FANG giant and Tesla rival are among this diverse group.
Via
Investor's Business Daily
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
November 12, 2021
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products.
Via
Talk Markets
President Biden Nominates Robert Califf As New FDA Commissioner: Report
November 12, 2021
Robert Califf was nominated today to lead the FDA for a second time. The White House reportedly ruled out Janet Woodcock after she faced opposition from some members of...
Via
Benzinga
Exposures
Product Safety
Why Are Biogen Shares Gaining Today?
November 12, 2021
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related:...
Via
Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
November 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...
Via
Benzinga
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
November 11, 2021
Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across...
Via
Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &...
Via
Benzinga
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
November 10, 2021
With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition....
Via
Benzinga
This Company Says Its New Topical Therapy Trials Bringing Hope to People Exposed to Biofilm Bacteria
November 09, 2021
Photo by Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...
Via
Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
How Are Biotech ETFs Reacting To These Q3 Earnings Releases?
November 06, 2021
There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see...
Via
Talk Markets
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Exposures
COVID-19
Healthcare Stocks Subject to Government Policy
November 02, 2021
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cassava Stock Could Jump More Than 200 Times
November 01, 2021
Cassava's Alzheimer's drug appears backed by strong data and plenty of public support. That's a winning combination for SAVA stock.
Via
InvestorPlace
Biogen Beat Earnings and Raised Guidance. Here's Why I Still Wouldn't Buy the Stock
October 29, 2021
Aduhelm remains a big question mark for the company.
Via
The Motley Fool
Will Chart Analysts Notice Bad Omen on Biogen's Chart
October 29, 2021
If history is any guide, there may be trouble ahead for shares of Biogen (NASDAQ:BIIB). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
Should Biogen Investors Be Preparing for the Worst?
October 27, 2021
With sagging sales and lackluster data in a recent trial, what does the future hold for shareholders?
Via
The Motley Fool
Why This Alzheimer's Study Missed, But That's Not Necessarily A Bad Thing For Cortexyme
October 26, 2021
Cortexyme said Tuesday its experimental Alzheimer's drug might work in some patients.
Via
Investor's Business Daily
10 Biggest Price Target Changes For Tuesday
October 26, 2021
Berenberg cut Kimberly-Clark Corporation (NYSE:KMB)...
Via
Benzinga
3 Big Problems With Biogen's Q3 Results
October 23, 2021
Sure, Biogen beat analysts' estimates in Q3. But the company still has some serious challenges.
Via
The Motley Fool
Athira CEO Resigns After Data Manipulation Firestorm, But Alzheimer's Stock Pops
October 22, 2021
Athira CEO Leen Kawas resigned after an investigation found she altered images.
Via
Investor's Business Daily
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
October 21, 2021
Cortexyme is testing a twice-day pill to treat Alzheimer's disease.
Via
Investor's Business Daily
10 Biggest Price Target Changes For Thursday
October 21, 2021
Wedbush boosted Tesla, Inc. (NASDAQ:TSLA) price ...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.